SMS Pharmaceuticals
- P/E
- 48.08
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 13.30%
- Debt to Equity
- 0.46
- EPS (TTM)
- ₹10.93
- Book Value
- ₹83.91
- Market Cap
- —
- P/E (TTM)
- 48.08
- P/B
- 6.26
- ROE
- 14.30%
- Dividend Yield
- 0.08%
- EBITDA
- ₹180 Cr
- 52W High
- ₹535.00
- 52W Low
- ₹270.10
- Volume
- 0
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| SMS Pharmaceuticals (this company) | ₹525.50 | 48.08 | ₹4,755 Cr | 6.26 | 0.08% | 14.30% | 13.30% | ₹898 Cr | ₹102 Cr |
| Median 8 companies | ₹1,587.70 | 43.45 | ₹1,25,337 Cr | 5.52 | 0.44% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 46
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 27
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 36
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 45
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 69
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
3- Stock is trading at 5.14 times its book value
- Company has a low return on equity of 12.3% over last 3 years.
- Company might be capitalizing the interest cost
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 5 | 1 | 13 |
| Oscillators | Strong Bearish | 5 | 1 | 3 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Strong Bearish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 70.32
- Bearish
- MACD (12,26,9)
- 19.16
- Bullish
- SMA (50)
- 435.42
- Bullish
- SMA (200)
- 391.74
- Bullish
As of
Analyst Rating
1 of 1 analyst rates Buy, 0 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +3.80% |
|---|---|
| 5Y | +9.52% |
| 3Y | +19.33% |
| 1Y | +13.28% |
| TTM | +10.20% |
Net profit
| 10Y | +9.54% |
|---|---|
| 5Y | +10.12% |
| 3Y | Turned to profit |
| 1Y | +47.83% |
| TTM | +41.67% |
Operating cash flow
| 10Y | −0.33% |
|---|---|
| 5Y | −8.10% |
| 3Y | +38.93% |
| 1Y | −28.05% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +4.82 pp |
|---|---|
| 5Y | −2.10 pp |
| 3Y | +8.85 pp |
| 1Y | +1.64 pp |
| TTM | +1.60 pp |
Revenue by year
| Mar 2017 | ₹438 Cr |
|---|---|
| Mar 2018 | ₹463 Cr |
| Mar 2019 | ₹465 Cr |
| Mar 2020 | ₹412 Cr |
| Mar 2021 | ₹563 Cr |
| Mar 2022 | ₹520 Cr |
| Mar 2023 | ₹522 Cr |
| Mar 2024 | ₹709 Cr |
| Mar 2025 | ₹783 Cr |
| Mar 2026 | ₹887 Cr |
Net profit by year
| Mar 2017 | ₹28.00 Cr |
|---|---|
| Mar 2018 | ₹32.00 Cr |
| Mar 2019 | ₹40.00 Cr |
| Mar 2020 | ₹32.00 Cr |
| Mar 2021 | ₹63.00 Cr |
| Mar 2022 | ₹62.00 Cr |
| Mar 2023 | −₹7.00 Cr |
| Mar 2024 | ₹50.00 Cr |
| Mar 2025 | ₹69.00 Cr |
| Mar 2026 | ₹102 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
SMS Pharmaceuticals Ltd is a mid-cap API manufacturer with a market cap of ₹3,944 Cr trading at a PE of 38.7x. The company has delivered strong recent profit growth (48% TTM, 155% 3-year CAGR) on improving operating margins (OPM expanding from 16.3% in FY24 to 19.1% in FY26), though its 3-year average ROE of 12% remains modest relative to its 5.02x price-to-book valuation.
- TTM profit growth of 48% significantly outpaces sales growth of 13%, indicating improving profitability and operating leverage
- 3-year compounded profit CAGR of 155% reflects a dramatic earnings recovery from the FY23 trough (net profit of just ₹3.88 Cr in FY23 to ₹102 Cr in FY26)
- Revenue has grown from ₹709 Cr in FY24 to ₹887 Cr in FY26, a healthy 3-year sales CAGR of 19%
- Operating profit margin expanded from 10.3% in FY23 to 19.1% in FY26, demonstrating sustained margin improvement
- Stock has delivered a 1-year return of 73% and a 3-year CAGR of 65%, reflecting strong market re-rating
- Interest costs declined from ₹23.46 Cr in FY24 to ₹18.54 Cr in FY25 before rising to ₹23.08 Cr in FY26, showing the company managed to reduce finance costs during its recovery phase
- Last year ROE improved to 14% versus the 3-year average of 12% and the 5-year average of 10%, showing an upward trajectory in capital efficiency
- PE of 38.7x is elevated for a company with a 10-year profit CAGR of only 10%, implying significant future growth is already priced in
- Price-to-book of 5.02x is high relative to 3-year average ROE of just 12.3%, suggesting the stock may not justify its valuation on return metrics alone
- 10-year sales CAGR of only 4% indicates historically slow top-line growth, raising questions about sustainability of recent acceleration
- Company might be capitalizing interest costs, which could flatter reported profits and understate true finance charges
- Dividend yield of just 0.09% (payout ratio ~3.7% in FY26) offers negligible income return to shareholders
- 5-year compounded profit CAGR of only 10% when viewed over a longer horizon tempers the recent surge narrative
- Interest costs rose 24% YoY from ₹18.54 Cr in FY25 to ₹23.08 Cr in FY26, suggesting rising debt or working capital needs even as the business scales
- 5-year stock CAGR of 19% versus the 3-year CAGR of 65% highlights that much of the re-rating is very recent and may not sustain
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Limited news flow for SMS Pharmaceuticals with only a routine disclosure confirming no change in promoter pledge status. No material positives or negatives emerged in the period. The lack of newsflow makes it difficult to assess directional momentum; investors should watch for upcoming quarterly results for clearer signals.
- No new promoter share pledges Jun 15
SMS Pharmaceuticals confirmed no new share encumbrances by promoters in FY26. Existing pledges for Mrs. Hima Bindu Potluri and group entities remain unchanged.
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 135 | 167 | 161 | 246 | 164 | 197 | 173 | 248 | 196 | 242 | 210 | 238 | 207 |
| Expenses | 109 | 139 | 132 | 212 | 131 | 165 | 140 | 207 | 157 | 194 | 167 | 198 | 166 |
| Operating Profit | 26 | 28 | 29 | 34 | 34 | 31 | 33 | 41 | 39 | 48 | 44 | 40 | 41 |
| OPM % | 19% | 17% | 18% | 14% | 20% | 16% | 19% | 16% | 20% | 20% | 21% | 17% | 20% |
| Other Income | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 4 | 3 | 2 |
| Interest | 6 | 6 | 6 | 6 | 5 | 5 | 4 | 5 | 6 | 6 | 6 | 5 | 6 |
| Depreciation | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 |
| PBT | 13 | 15 | 17 | 22 | 22 | 20 | 22 | 29 | 24 | 34 | 31 | 27 | 27 |
| Tax % | 31% | 21% | 26% | 26% | 25% | 29% | 24% | 30% | 23% | 26% | 26% | 23% | 26% |
| Net Profit | 9 | 12 | 11 | 17 | 16 | 14 | 18 | 20 | 20 | 25 | 23 | 33 | 21 |
| EPS (₹) | 1.1 | 1.38 | 1.36 | 2.04 | 1.95 | 1.66 | 2.15 | 2.29 | 2.31 | 2.7 | 2.51 | 3.49 | 2.23 |
Profit & Loss
₹ Cr| Particulars | Mar 2007 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 193 | 611 | 438 | 463 | 465 | 412 | 563 | 520 | 522 | 709 | 783 | 887 | 898 |
| Expenses | 145 | 522 | 363 | 369 | 375 | 332 | 442 | 405 | 467 | 593 | 644 | 715 | 725 |
| Operating Profit | 47 | 89 | 75 | 93 | 90 | 80 | 121 | 115 | 55 | 117 | 139 | 172 | 173 |
| OPM % | 25% | 15% | 17% | 20% | 19% | 19% | 22% | 22% | 10% | 16% | 18% | 19% | 19% |
| Other Income | 5 | 4 | 1 | 2 | 3 | 5 | 3 | 5 | 5 | 4 | 6 | 8 | 9 |
| Interest | 8 | 17 | 16 | 15 | 12 | 12 | 11 | 19 | 22 | 24 | 19 | 23 | 23 |
| Depreciation | 5 | 19 | 19 | 20 | 19 | 22 | 22 | 32 | 32 | 32 | 34 | 40 | 40 |
| PBT | 40 | 56 | 42 | 60 | 62 | 51 | 91 | 68 | 5 | 66 | 92 | 117 | 119 |
| Tax % | 36% | 26% | 14% | 33% | 34% | 36% | 33% | 1% | 28% | 26% | 27% | 25% | — |
| Net Profit | 25 | 41 | 28 | 32 | 40 | 32 | 63 | 62 | −7 | 50 | 69 | 102 | 102 |
| EPS (₹) | 2.55 | 4.83 | 3.36 | 3.75 | 4.73 | 3.73 | 7.38 | 7.35 | −0.83 | 5.88 | 7.8 | 10.89 | 10.93 |
| Div. Payout % | 8% | 4% | 6% | 7% | 5% | 7% | 4% | 4% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | 7% | 5% | 4% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2007 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| Reserves | 182 | 285 | 246 | 276 | 313 | 340 | 402 | 462 | 452 | 528 | 631 | 776 |
| Borrowings | 73 | 204 | 149 | 146 | 144 | 157 | 255 | 263 | 254 | 281 | 311 | 365 |
| Other Liabilities | 64 | 158 | 89 | 72 | 93 | 103 | 147 | 126 | 165 | 217 | 202 | 212 |
| Total Liabilities | 329 | 656 | 493 | 503 | 559 | 608 | 812 | 860 | 880 | 1,034 | 1,153 | 1,362 |
| Fixed Assets | 69 | 370 | 290 | 279 | 281 | 280 | 457 | 438 | 412 | 437 | 533 | 534 |
| CWIP | 15 | 13 | 8 | 8 | 18 | 42 | 7 | 11 | 33 | 30 | 35 | 122 |
| Investments | 0 | 21 | 29 | 28 | 27 | 26 | 27 | 22 | 11 | 11 | 12 | 26 |
| Other Assets | 245 | 252 | 166 | 187 | 232 | 259 | 321 | 389 | 424 | 556 | 573 | 681 |
| Total Assets | 329 | 656 | 493 | 503 | 559 | 608 | 812 | 860 | 880 | 1,034 | 1,153 | 1,362 |
Cash Flow
₹ Cr| Particulars | Mar 2007 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 14 | 61 | 73 | 32 | 50 | 40 | 90 | 45 | 22 | 50 | 82 | 59 |
| Investing | −32 | −97 | −39 | −17 | −35 | −43 | −152 | −27 | −30 | −52 | −123 | −131 |
| Financing | 107 | 27 | −33 | −15 | −13 | −2 | 92 | −12 | −32 | 31 | 47 | 76 |
| Net Cash Flow | 89 | −9 | 1 | 0 | 2 | −5 | 31 | 6 | −39 | 29 | 5 | 4 |
| Free Cash Flow | −5 | −27 | 50 | 23 | 15 | −3 | −61 | 18 | −7 | −2 | −42 | −71 |
| CFO/EBITDA | 42 | 93 | 110 | 46 | 70 | 65 | 88 | 52 | 50 | 56 | 73 | 49 |
Ratios
| Particulars | Mar 2007 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 114 | 36 | 18 | 19 | 20 | 43 | 68 | 34 | 104 | 122 | 95 | 89 |
| Inventory Days | 165 | 106 | 114 | 135 | 170 | 191 | 148 | 333 | 243 | 201 | 241 | 260 |
| Days Payable | 72 | 79 | 82 | 49 | 59 | 66 | 70 | 97 | 117 | 130 | 96 | 89 |
| Cash Conversion Cycle | 206 | 63 | 50 | 105 | 131 | 169 | 146 | 270 | 230 | 192 | 239 | 260 |
| Working Capital Days | 169 | 19 | −2 | 27 | 39 | 57 | 48 | 94 | 104 | 85 | 88 | 98 |
| ROCE % | — | — | 13% | 18% | 17% | 13% | 17% | 13% | 4% | 12% | 13% | 13% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view SMS Pharmaceuticals insights
73 extracted metrics across FY07–FY27.
Documents
- Q1 FY27 concall · Aug 2026PPT
- Concall · May 2026Transcript PPT
- Q3 FY26 concall · Feb 2026PPT
- Q2 FY26 concall · Nov 2025Transcript PPT Recording
- Q1 FY26 concall · Aug 2025PPT
- 9 Aug 2025
- 9 Sep 2026
- 4 Dec 2025
- 10 Oct 2024
- 7 Dec 2023
- 3 Nov 2022
- General announcements 2 Nov 2026
Frequently Asked Questions about SMS Pharmaceuticals
What does SMS Pharmaceuticals Ltd do?
Where is SMS Pharmaceuticals Ltd (SMSPHARMA) listed?
Which sector does SMS Pharmaceuticals Ltd belong to?
What is the PE ratio of SMS Pharmaceuticals Ltd?
What is the 52-week high and low of SMS Pharmaceuticals Ltd?
Does SMS Pharmaceuticals Ltd pay dividends?
What is the Return on Equity (ROE) of SMS Pharmaceuticals Ltd?
Company Information
SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SMSPHARMA.md for SMS Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.